AI and cancer: your questions

Can AI interpret my NGS genomic report?

AI can explain the terms in an NGS report, but studies show it cannot yet match a molecular tumour board on treatment. Here is how to use it safely.

Can AI explain my NGS report?

AI can explain the words in a next-generation sequencing (NGS) report, such as variant, VUS, TMB and MSI, and help you list questions. It cannot yet decide which treatment fits your gene changes. In a 2023 JAMA Network Open study, four AI chatbots suggested treatments for fictional cases, and a molecular tumour board found their suggestions fell well short of a human expert's. Treatment choices from an NGS report need your oncologist. Using AI the right way can make your appointment more useful.

What is in an NGS report

  • Variants: gene changes found in the tumour, often sorted into four tiers, from strong clinical significance to benign.
  • VUS: a variant of unknown significance, which usually should not change treatment.
  • TMB and MSI: markers that can make some patients eligible for immunotherapy, whatever the cancer type.
  • Evidence levels: databases such as OncoKB grade how strongly a gene change is linked to a drug.

The limits

AI studies on NGS reports mostly use fictional cases, and none shows better outcomes. Experts say AI needs close supervision by a molecular tumour board. Some AI answers also miss new approvals, so always check the date of the evidence. Researchers are now testing expert-guided systems that look up references and learn from tumour board feedback, such as MEREDITH in Germany. Early results improved agreement with clinicians, but these systems are tested on fictional cases and still need a molecular tumour board to check every suggestion.

Questions to ask your doctor

Take these to your next appointment:

  • Which gene changes on my report matter for treatment?
  • Is there a targeted therapy or immunotherapy that fits these results?
  • Can a molecular tumour board review my report?
  • Do any clinical trials match my gene changes?

Where OncoVOIS fits

OncoVOIS, a CancerFax cancer-navigation app, explains NGS terms in plain words and helps you prepare questions about targeted therapy and trials. It is available on Google Play for Android phones, and the CancerFax team can help with expert opinions and trials.

Sources

1. Li MM, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer (AMP/ASCO/CAP). Journal of Molecular Diagnostics, 2017. https://doi.org/10.1016/j.jmoldx.2016.10.002 2. Benary M, et al. Leveraging large language models for decision support in personalized oncology. JAMA Network Open, 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10656647 3. National Cancer Institute. FDA approves pembrolizumab for tumors with high mutational burden, 2020. https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-pembrolizumab-tmb-approval-genomic-testing 4. Memorial Sloan Kettering. FDA recognizes MSK's OncoKB database, 2021. https://www.mskcc.org/news/milestone-precision-oncology-fda-gives-green-light-msk-s-genetic-database 5. Lammert J, et al. Expert-guided large language models for clinical decision support in precision oncology. JCO Precision Oncology, 2024. https://doi.org/10.1200/PO-24-00478

Frequently asked questions

What is an NGS report in cancer?

An NGS (next-generation sequencing) report lists gene changes found in a tumour sample or blood. It may show variants, their likely importance, and markers such as tumour mutational burden (TMB) and microsatellite instability (MSI). Your oncologist uses it, along with the cancer type and stage, to see whether targeted therapy, immunotherapy or a trial may help.

Can ChatGPT choose a treatment from my NGS report?

No. In a 2023 JAMA Network Open study, four AI chatbots suggested treatments for 10 fictional cases. A molecular tumour board found their suggestions did not reach the quality of a human expert, though a few useful options did come up. Use AI to understand terms, and let your oncologist decide treatment.

What does VUS mean on a genomic report?

VUS means variant of unknown significance. It is a gene change that scientists cannot yet link clearly to cancer or to a treatment. Under the 2017 AMP/ASCO/CAP guideline it is Tier III. A VUS usually should not change your treatment, but it can be reclassified later as more is learned, so keep your report.

What are TMB and MSI on my report?

TMB, tumour mutational burden, counts gene changes in the tumour; a high TMB is at least 10 mutations per megabase. MSI-high, or mismatch repair deficiency, means the tumour has trouble fixing DNA errors. Both can make some patients eligible for immunotherapy such as pembrolizumab, whatever the cancer type. Your oncologist decides if it fits.

What is a molecular tumour board?

A molecular tumour board is a meeting of oncologists, pathologists, geneticists and other experts who review genomic results together and recommend options. Studies of AI tools for NGS reports compare them against such boards, and experts say AI needs close supervision by one. Ask your hospital whether your report can be reviewed by a tumour board.

What is OncoKB?

OncoKB is a precision-oncology knowledge base from Memorial Sloan Kettering that grades how strongly a gene change is linked to a treatment. In 2021 it became the first tumour mutation database partially recognised by the US FDA. Laboratories and oncologists use resources like it to interpret NGS results.

Can an NGS report find me a clinical trial?

It can help. Some trials enrol patients based on specific gene changes, so your NGS results may open trial options. Eligibility also depends on cancer type, stage, past treatment and health. Ask your oncologist, or the CancerFax team, to check trials that match your report.

How can OncoVOIS help with my NGS report?

OncoVOIS, from CancerFax, reads your NGS report and explains terms such as variant, VUS, TMB and MSI in plain words, by text or voice. It helps you prepare questions about targeted therapy, immunotherapy and trials for your oncologist. It does not choose treatment from your report.

This page is general information, not medical advice. OncoVOIS explains and helps you prepare; your oncologist decides about your care.